Sinusitis (Ear Nose Throat Disorders) – Drugs In Development, 2021

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Sinusitis – Drugs In Development, 2021, provides an overview of the Sinusitis (Ear Nose Throat Disorders) pipeline landscape.

Sinusitis is characterized by inflammation of the sinuses. This inflammation usually stems from infection caused by a viral or bacterial infection or by an allergy Symptoms include congestion and obstruction in the nose, pain, tenderness, hyposmia, halitosis, cough, toothache, headache and pain over the cheeks just below the eyes. Risk factors include asthma, nasal passage abnormality, immune system disorder, such as HIV/AIDS or cystic fibrosis and another allergic condition.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Sinusitis – Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Sinusitis (Ear Nose Throat Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Sinusitis (Ear Nose Throat Disorders) pipeline guide also reviews of key players involved in therapeutic development for Sinusitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 4, 5, 5, 1, 11, 2 and 1 respectively.

Sinusitis (Ear Nose Throat Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Sinusitis (Ear Nose Throat Disorders).

– The pipeline guide reviews pipeline therapeutics for Sinusitis (Ear Nose Throat Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

– The pipeline guide reviews key companies involved in Sinusitis (Ear Nose Throat Disorders) therapeutics and enlists all their major and minor projects.

– The pipeline guide evaluates Sinusitis (Ear Nose Throat Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

– The pipeline guide reviews latest news related to pipeline therapeutics for Sinusitis (Ear Nose Throat Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Sinusitis (Ear Nose Throat Disorders).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Sinusitis (Ear Nose Throat Disorders) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies mentioned

Amgen Inc

AnaptysBio Inc

Aodh Lifesciences Pvt Ltd

Argenx SE

Armata Pharmaceuticals

ConMed Biosciences Inc

Furen Pharmaceutical Group Co Ltd

GeneOne Life Science Inc

Genrix (Shanghai) Biopharmaceutical Co Ltd

GlaxoSmithKline Plc

GlycoMira Therapeutics Inc

IVIEW Therapeutics Inc

Kyowa Kirin Co Ltd

Lyra Therapeutics Inc

Maxwell Biosciences Inc

Table of Contents

Table of Contents

Introduction

Sinusitis - Overview

Sinusitis - Therapeutics Development

Sinusitis - Therapeutics Assessment

Sinusitis - Companies Involved in Therapeutics Development

Sinusitis - Drug Profiles

Sinusitis - Dormant Projects

Sinusitis - Discontinued Products

Sinusitis - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Sinusitis, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Companies, 2021 (Contd..1)

Products under Development by Companies, 2021

Products under Development by Companies, 2021 (Contd..1)

Number of Products by Stage and Target, 2021

Number of Products by Stage and Mechanism of Action, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Sinusitis – Pipeline by Amgen Inc, 2021

Sinusitis – Pipeline by AnaptysBio Inc, 2021

Sinusitis – Pipeline by Aodh Lifesciences Pvt Ltd, 2021

Sinusitis – Pipeline by Argenx SE, 2021

Sinusitis – Pipeline by Armata Pharmaceuticals, 2021

Sinusitis – Pipeline by ConMed Biosciences Inc, 2021

Sinusitis – Pipeline by Furen Pharmaceutical Group Co Ltd, 2021

Sinusitis – Pipeline by GeneOne Life Science Inc, 2021

Sinusitis – Pipeline by Genrix (Shanghai) Biopharmaceutical Co Ltd, 2021

Sinusitis – Pipeline by GlaxoSmithKline Plc, 2021

Sinusitis – Pipeline by GlycoMira Therapeutics Inc, 2021

Sinusitis – Pipeline by IVIEW Therapeutics Inc, 2021

Sinusitis – Pipeline by Kyowa Kirin Co Ltd, 2021

Sinusitis – Pipeline by Lyra Therapeutics Inc, 2021

Sinusitis – Pipeline by Maxwell Biosciences Inc, 2021

Sinusitis – Pipeline by Merck & Co Inc, 2021

Sinusitis – Pipeline by Nexeos Bio, 2021

Sinusitis – Pipeline by Nota Laboratories LLC, 2021

Sinusitis – Pipeline by OptiNose Inc, 2021

Sinusitis – Pipeline by Pfizer Inc, 2021

Sinusitis – Pipeline by ProclaRx LLC, 2021

Sinusitis – Pipeline by Quorum Innovations LLC, 2021

Sinusitis – Pipeline by RAPT Therapeutics Inc, 2021

Sinusitis – Pipeline by Recce Pharmaceuticals Ltd, 2021

Sinusitis – Pipeline by Regeneron Pharmaceuticals Inc, 2021

Sinusitis – Pipeline by SaNOtize Research and Development Corp, 2021

Sinusitis – Pipeline by Suzhou Connect Biopharmaceuticals Ltd, 2021

Sinusitis – Pipeline by Wuhan Yicheng Biotechnology Co Ltd, 2021

Sinusitis – Dormant Projects, 2021

Sinusitis – Dormant Projects, 2021 (Contd..1)

Sinusitis – Discontinued Products, 2021

List of Figures

List of Figures

Number of Products under Development for Sinusitis, 2021

Number of Products under Development by Companies, 2021

Number of Products by Top 10 Targets, 2021

Number of Products by Stage and Top 10 Targets, 2021

Number of Products by Top 10 Mechanism of Actions, 2021

Number of Products by Stage and Top 10 Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Routes of Administration, 2021

Number of Products by Molecule Types, 2021

Number of Products by Stage and Molecule Types, 2021

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports